Cite

HARVARD Citation

    Megaro, G. et al. (2022). Long‐term response to crizotinib in a 17‐year‐old boy with treatment‐naïve ALK‐positive non‐small‐cell lung cancer. Cancer reports. 5 (3), p. n/a. [Online]. 
  
Back to record